18F-DCFPyL PET/CT in metastatic renal cell carcinoma

Geoffrey M Currie; Marko Trifunovic; Jui Liu; Sang Kim; Howard Gurney

doi:10.2967/jnmt.121.262799

18F-DCFPyL PET/CT in metastatic renal cell carcinoma

Geoffrey M Currie, Marko Trifunovic, Jui Liu, Sang Kim, Howard Gurney

Dentistry and Medical Sciences

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Targeted molecular imaging with PET uses chemical ligands that are peptides specifically targeting a receptor of interest. Prostate-specific membrane antigen (PSMA) is substantially upregulated in prostate cancer but is also expressed in the neovascular tissue of several malignancies, including renal cell carcinoma (RCC). Radiolabeled peptide targets for PSMA may be helpful in detecting metastatic RCC lesions. We present a case of incidental detection of RCC metastatic disease with PSMA-targeted PET, and we explore potential use for deliberate evaluation of RCC with PSMA-targeted tracers.

Original language	English
Pages (from-to)	282-285
Number of pages	4
Journal	Journal of Nuclear Medicine Technology
Volume	50
Issue number	3
Early online date	08 Nov 2021
DOIs	https://doi.org/10.2967/jnmt.121.262799
Publication status	Published - 01 Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2967/jnmt.121.262799

Cite this

@article{ae30bfed89934d87b8e2930a5b52615e,

title = "18F-DCFPyL PET/CT in metastatic renal cell carcinoma",

abstract = "Targeted molecular imaging with PET uses chemical ligands that are peptides specifically targeting a receptor of interest. Prostate-specific membrane antigen (PSMA) is substantially upregulated in prostate cancer but is also expressed in the neovascular tissue of several malignancies, including renal cell carcinoma (RCC). Radiolabeled peptide targets for PSMA may be helpful in detecting metastatic RCC lesions. We present a case of incidental detection of RCC metastatic disease with PSMA-targeted PET, and we explore potential use for deliberate evaluation of RCC with PSMA-targeted tracers.",

keywords = "18F-PSR, metastases, PET/CT, RCC",

author = "Currie, {Geoffrey M} and Marko Trifunovic and Jui Liu and Sang Kim and Howard Gurney",

note = "Publisher Copyright: {\textcopyright} 2022 by the Society of Nuclear Medicine and Molecular Imaging.",

year = "2022",

month = sep,

day = "1",

doi = "10.2967/jnmt.121.262799",

language = "English",

volume = "50",

pages = "282--285",

journal = "Journal of Nuclear Medicine Technology",

issn = "0091-4916",

publisher = "Society of Nuclear Medicine and Molecular Imaging",

number = "3",

}

TY - JOUR

T1 - 18F-DCFPyL PET/CT in metastatic renal cell carcinoma

AU - Currie, Geoffrey M

AU - Trifunovic, Marko

AU - Liu, Jui

AU - Kim, Sang

AU - Gurney, Howard

PY - 2022/9/1

Y1 - 2022/9/1

N2 - Targeted molecular imaging with PET uses chemical ligands that are peptides specifically targeting a receptor of interest. Prostate-specific membrane antigen (PSMA) is substantially upregulated in prostate cancer but is also expressed in the neovascular tissue of several malignancies, including renal cell carcinoma (RCC). Radiolabeled peptide targets for PSMA may be helpful in detecting metastatic RCC lesions. We present a case of incidental detection of RCC metastatic disease with PSMA-targeted PET, and we explore potential use for deliberate evaluation of RCC with PSMA-targeted tracers.

AB - Targeted molecular imaging with PET uses chemical ligands that are peptides specifically targeting a receptor of interest. Prostate-specific membrane antigen (PSMA) is substantially upregulated in prostate cancer but is also expressed in the neovascular tissue of several malignancies, including renal cell carcinoma (RCC). Radiolabeled peptide targets for PSMA may be helpful in detecting metastatic RCC lesions. We present a case of incidental detection of RCC metastatic disease with PSMA-targeted PET, and we explore potential use for deliberate evaluation of RCC with PSMA-targeted tracers.

KW - 18F-PSR

KW - metastases

KW - PET/CT

KW - RCC

UR - http://www.scopus.com/inward/record.url?scp=85139572519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139572519&partnerID=8YFLogxK

U2 - 10.2967/jnmt.121.262799

DO - 10.2967/jnmt.121.262799

M3 - Article

C2 - 34750233

SN - 0091-4916

VL - 50

SP - 282

EP - 285

JO - Journal of Nuclear Medicine Technology

JF - Journal of Nuclear Medicine Technology

IS - 3

ER -

18F-DCFPyL PET/CT in metastatic renal cell carcinoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this